| 5-fluorouracil: mechanisms of action and clinical strategies DB Longley, DP Harkin, PG Johnston Nature reviews cancer 3 (5), 330-338, 2003 | 5903 | 2003 |
| Cancer drug resistance: an evolving paradigm C Holohan, S Van Schaeybroeck, DB Longley, PG Johnston Nature Reviews Cancer 13 (10), 714-726, 2013 | 4652 | 2013 |
| Molecular mechanisms of drug resistance DB Longley, PG Johnston The Journal of Pathology: A Journal of the Pathological Society of Great …, 2005 | 1917 | 2005 |
| Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan J Boyer, EG McLean, S Aroori, P Wilson, A McCulla, PD Carey, ... Clinical cancer research 10 (6), 2158-2167, 2004 | 281 | 2004 |
| c-FLIP inhibits chemotherapy-induced colorectal cancer cell death DB Longley, TR Wilson, M McEwan, WL Allen, U McDermott, L Galligan, ... Oncogene 25 (6), 838-848, 2006 | 250 | 2006 |
| Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue RD Kennedy, M Bylesjo, P Kerr, T Davison, JM Black, EW Kay, RJ Holt, ... Journal of Clinical Oncology 29 (35), 4620-4626, 2011 | 230 | 2011 |
| Chemoresistance in solid tumours TR Wilson, DB Longley, PG Johnston Annals of Oncology 17 (10), x315, 2006 | 225 | 2006 |
| Anti-apoptotic mechanisms of drug resistance in cancer TR Wilson, PG Johnston, DB Longley Current cancer drug targets 9 (3), 307-319, 2009 | 216 | 2009 |
| Drug resistance, predictive markers and pharmacogenomics in colorectal cancer DB Longley, WL Allen, PG Johnston Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1766 (2), 184-196, 2006 | 202 | 2006 |
| Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP L Galligan, DB Longley, M McEwan, TR Wilson, K McLaughlin, ... Molecular cancer therapeutics 4 (12), 2026-2036, 2005 | 195 | 2005 |
| Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling PJ Maxwell, DB Longley, T Latif, J Boyer, W Allen, M Lynch, U McDermott, ... Cancer research 63 (15), 4602-4606, 2003 | 175 | 2003 |
| Challenging the cancer molecular stratification dogma: intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer PD Dunne, DG McArt, CA Bradley, PG O'Reilly, HL Barrett, R Cummins, ... Clinical Cancer Research 22 (16), 4095-4104, 2016 | 161 | 2016 |
| c-FLIP: a key regulator of colorectal cancer cell death TR Wilson, KM McLaughlin, M McEwan, H Sakai, KMA Rogers, ... Cancer research 67 (12), 5754-5762, 2007 | 154 | 2007 |
| The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates DB Longley, J Boyer, WL Allen, T Latif, PR Ferguson, PJ Maxwell, ... Cancer research 62 (9), 2644-2649, 2002 | 153 | 2002 |
| Resistance mechanisms to cancer chemotherapy KM Redmond, TR Wilson, PG Johnston, DB Longley Front Biosci 13, 5138-5154, 2008 | 141 | 2008 |
| Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer J Boyer, WL Allen, EG McLean, PM Wilson, A McCulla, S Moore, ... Cancer research 66 (5), 2765-2777, 2006 | 135 | 2006 |
| Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non–small cell lung cancer cells S Van Schaeybroeck, J Kyula, DM Kelly, A Karaiskou-McCaul, ... Molecular cancer therapeutics 5 (5), 1154-1165, 2006 | 133 | 2006 |
| Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy S Van Schaeybroeck, A Karaiskou-McCaul, D Kelly, D Longley, ... Clinical cancer research 11 (20), 7480-7489, 2005 | 124 | 2005 |
| AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer PD Dunne, DG McArt, JK Blayney, M Kalimutho, S Greer, T Wang, ... Clinical Cancer Research 20 (1), 164-175, 2014 | 115 | 2014 |
| Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer JN Kyula, S Van Schaeybroeck, J Doherty, CS Fenning, DB Longley, ... Clinical Cancer Research 16 (13), 3378-3389, 2010 | 115 | 2010 |
